Abstract:Background: Programmed cell death ligand 1 (PD-L1) plays a critical role in the tumor microenvironment and overexpression in several solid cancers has been reported. This was associated with a downregulation of the local immune response, specifically of T-cells. Immune checkpoint inhibitors showed a potential to break this localized immune paralysis, but only 30% of patients are considered responders. New diagnostic approaches are therefore needed to determine patient eligibility. Small molecule radiotracers targeting PD-L1, may serve as such diagnostic tools, addressing the heterogeneous PD-L1 expression between and within tumor lesions, thus aiding in therapy decisions. Results: Four biphenyl-based small-molecule PD-L1 ligands were synthesized using a convergent synthetic route with a linear sequence of up to eleven steps. As a chelator NODA-GA, CB-TE2A or DiAmSar was used to allow radiolabeling with copper-64 ([64Cu]Cu-14-[64Cu]Cu-16). In addition, a dimeric structure based on DiAmSar was synthesized ([64Cu]Cu-17). All four radioligands exhibited high proteolytic stability (> 95%) up to 48 h post-radiolabeling. Saturation binding yielded moderate affinities toward PD-L1, ranging from 100 to 265 nM. Real-time radioligand binding provided more promising KD values around 20 nM for [64Cu]Cu-14 and [64Cu]Cu-15. In vivo PET imaging in mice bearing both PC3 PD-L1 overexpressing and PD-L1-mock tumors was performed at 0-2, 4-5 and 24-25 h post injection (p.i.). This revealed considerably different pharmacokinetic profiles, depending on the substituted chelator. [64Cu]Cu-14, substituted with NODA-GA, showed renal clearance with low liver uptake, whereas substitution with the cross-bridged cyclam chelator CB-TE2A resulted in a primarily hepatobiliary clearance. Notably, the monomeric DiAmSar radioligand [64Cu]Cu-16 demonstrated a higher liver uptake than [64Cu]Cu-15, but was still renally cleared as evidenced by the lack of uptake in gall bladder and intestines. The dimeric structure [64Cu]Cu-17 showed extensive accumulation and trapping in the liver but was also cleared via the renal pathway. Of all tracer candidates and across all timepoints, [64Cu]Cu-17 showed the highest accumulation at 24 h p.i. in the PD-L1-overexpressing tumor of all timepoints and all radiotracers, indicating drastically increased circulation time upon dimerization of two PD-L1 binding motifs. Conclusions: This study shows that chelator choice significantly influences the pharmacokinetic profile of biphenyl-based small molecule PD-L1 radioligands. The NODA-GA-conjugated radioligand [64Cu]Cu-14 exhibited favorable renal clearance; however, the limited uptake in tumors suggests the need for structural modifications to the binding motif for future PD-L1 radiotracers.

64Cu Tumor Labeling with Hexadentate Picolinic Acid‐Based Bispidine Immunoconjugates

64 Cu tumor labeling with hexadentate picolinic acid‐based bispidine immunoconjugates

Copper(II) Complexes of 2,2'- Bis dipyrrins: Synthesis, Characterization, Cell Uptake, and Radiolabeling with Copper-64

64 Cu-Labeled Boron-Containing Cyclic RGD Peptides for BNCT and PET Imaging

64Cu2+ Complexes of Tripodal Amine Ligands' In Vivo Tumor and Liver Uptakes and Intracellular Cu Distribution in the Extrahepatic Bile Duct Carcinoma Cell Line TFK-1: A Basic Comparative Study

Radio-synthesis, Quality Control and Micro-PET Imaging of Cu-64-DOTA-TATE

Recent Advances in Preclinical Studies of the Theranostic Agent [64Cu]CuCl2

Radio-Labeling and Micro-Pet Study of Cu-64 Labeled D-Glucose for Tumor Imaging

A new chelator-free multifunctional [64Cu]CuS nanoparticle platform for simultaneous µPET/CT imaging and radiotherapy

Chelator impact: investigating the pharmacokinetic behavior of copper-64 labeled PD-L1 radioligands

Design and Bio.Evaluation of Cu-64-Nota-Herceptin for Tumor Targeted Micro-Pet Imaging

The heterobivalent (SSTR2/albumin) radioligand [67Cu]Cu-NODAGA-cLAB4-TATE enables efficient somatostatin receptor radionuclide theranostics

Synthesis and Radiolabeling of (64)Cu-Labeled 2-Nitroimidazole Derivative (64)Cu-Bms2p2 for Hypoxia Imaging.

64Cus-Labeled Nanoparticles: a New Sentinel-Lymph-node-mapping Agent for PET-CT and Photoacoustic Tomography

Integrin αvβ3-Targeted [ 64 Cu]CuS Nanoparticles for PET/CT Imaging and Photothermal Ablation Therapy.

Development of [ 64 Cu]Cu-BPAMD for PET imaging of bone metastases

Evaluation of 64cu Radiolabeled Anti-Hpd-l1 Nb6 for Positron Emission Tomography Imaging in Lung Cancer Tumor Mice Model

[64Cu]CuS nanoparticles as a dual PET/CT and photoacoustic imaging agent for sentinel lymph nodes mapping

Renal-Clearable Ultrasmall Coordination Polymer Nanodots for Chelator-Free 64Cu-Labeling and Imaging-Guided Enhanced Radiotherapy of Cancer.

64Cu radiolabeled nanomaterials for positron emission tomography (PET) imaging

Cu-64-Doped Pdcu@Au Tripods: A Multifunctional Nanomaterial For Positron Emission Tomography And Image-Guided Photothermal Cancer Treatment